Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions. You may request a live medical interpreter for a discussion about your care.
Taking part in the Older Adult Hematologic Malignancy (OHM) Program is voluntary. If you are a patient aged 75 or older who comes to Dana-Farber/Brigham and Women's Cancer Center for treatment of your blood cancer, you will be approached to take part
in the program, beginning with a 10-minute assessment by our research assistant.
In addition, as a patient in the OHM Program:
Patients age 75 and older are at higher risk for treatment complications — partly because they are likely to have other age-related illnesses, such as diabetes or high blood pressure. Including the expertise of a geriatrician in the treatment plan helps
guide therapy decisions, minimizing side effects and enhancing the patient's overall quality of life. If you are an older adult, here are some reasons to consider this special type of care for your cancer:
These options include various types of chemotherapy, and enrollment in clinical trials. Another choice appropriate for some blood cancers is to monitor patients, and treat them when necessary with care directed at symptoms alone. In some cases, patients
may choose to have supportive care only.
We can offer more intensive treatments than older patients would be likely to receive in the community, based on their preferences and functional age, rather than their calendar age. With the help of Drs. Driver and Hshieh, we can also eliminate unnecessary
or potentially harmful medications, and help organize exercise and physical therapy, home visits by caregivers, and medication management.
Appointments and Second Opinions
OHM research assistant Richard Chen assesses all patients.